Oxaliplatin news

All news on Oxaliplatin: plants, production capacities, investments and involved companies.

29 June 2026

Genmab: EPCORE DLBCL-4 shows PFS benefit for epcoritamab plus lenalidomide

Phase 3 topline: fixed‑duration subcutaneous epcoritamab + lenalidomide significantly reduced progression/death versus R‑GemOx in relapsed/refractory DLBCL; safety consistent with known profiles.
18 June 2026

Roche: FDA accepts sBLA for subcutaneous Lunsumio VELO plus Polivy in relapsed/refractory LBCL

sBLA accepted based on phase III SUNMO showing 59% reduction in progression risk; FDA decision expected by 9 Feb 2027.
17 June 2026

Genentech seeks FDA approval for Lunsumio VELO plus Polivy in relapsed/refractory LBCL

sBLA accepted for subcutaneous bispecific + ADC combo in relapsed/refractory large B‑cell lymphoma; FDA decision expected Feb 9, 2027.
10 June 2026

Genentech: FDA grants Priority Review for Tecentriq plus chemotherapy in stage III dMMR/MSI‑H colon cancer

FDA accepted an sBLA for adjuvant PD‑L1 therapy plus chemotherapy in stage III dMMR/MSI‑H colon cancer; agency decision expected Oct 9, 2026.
23 March 2026

Chugai obtains MHLW approval for Lunsumio–Polivy combo in relapsed/refractory large B‑cell lymphoma

Japan approves Lunsumio + Polivy for relapsed/refractory large B‑cell lymphoma after Phase III SUNMO: ORR 69.7%, PFS 11.5 vs 3.8 months (59% lower progression/death risk); manageable safety.
16 January 2026

Genmab Reports Phase 3 Trial Results for Epcoritamab in Relapsed/Refractory DLBCL

Epcoritamab shows improved progression-free survival in Phase 3 trial for R/R DLBCL. Safety profile consistent. Further analysis and regulatory discussions planned.

Who will be producing Oxaliplatin in the future?

Find out with chemXplore Alpha

Learn more

8 December 2025

Roche's Columvi Combo Shows Sustained Survival Benefit in Phase III Study

Columvi with GemOx doubles survival in R/R DLBCL patients, approved in 50+ countries, offering a non-transplant treatment option.